Stabilization of Nrf2 leading to HO-1 activation protects against zinc oxide nanoparticles-induced endothelial cell death

With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxid...

Full description

Saved in:
Bibliographic Details
Published inNanotoxicology Vol. 15; no. 6; pp. 779 - 797
Main Authors Zhang, Longbin, Zou, Liyong, Jiang, Xuejun, Cheng, Shuqun, Zhang, Jun, Qin, Xia, Qin, Zhexue, Chen, Chengzhi, Zou, Zhen
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 03.07.2021
Taylor & Francis Ltd
Subjects
Online AccessGet full text

Cover

Loading…
Abstract With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity.
AbstractList With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity.
With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity.With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns. Oxidative stress is recognized as the most important outcome of the toxicity induced by ZnONPs. The Nrf2-Keap1 system and its downstream antioxidative genes are the fundamental protective mechanisms for redox hemeostasis. However, the detailed mechanisms of Nrf2 activation in ZnONPs-treated endothelial cells and murine blood vessels have yet to be elucidated. Herein, we show that Nrf2 was activated and played a negative role in cell death induced by ZnONPs. Moreover, we demonstrate that HO-1 was the most extensively upregulated antioxidative gene-activated by Nrf2. Forced overexpression of HO-1, pharmacological activation of HO-1 with the agonists RTA-408 (omaveloxolone, an FDA-approved drug) and RTA-402 repressed cell death, and treatment with HO-1 antagonist SnPP exacerbated the cell death. Importantly, loss of HO-1 diminished the cytoprotective role induced by Nrf2 in ZnONPs-treated HUVEC cells, indicating that the Nrf2-HO-1 axis was the crucial regulatory mechanism for the antioxidative response in the context of ZnONPs-induced endothelial damage. Mechanistically, we demonstrate that the p62-Keap1 axis was not involved in the activation of Nrf2. Intriguingly, the degradation half-life of Nrf2 in HUVEC cells was increased from less than 1 h under quiescent conditions to approximately 6 h under ZnONPs treatment condition; moreover, ZnONPs treatment induced activation of Nrf2/HO-1 and accumulation of ubiquitin in the aorta ventralis of mouse, suggesting that the ubiquitin-proteasome system had been perturbed, which subsequently led to the stabilization of Nrf2 and activation of HO-1. This study might contribute to a better understanding of ZnONPs-associated toxicity.
Author Zou, Liyong
Cheng, Shuqun
Zhang, Longbin
Zou, Zhen
Qin, Zhexue
Qin, Xia
Chen, Chengzhi
Jiang, Xuejun
Zhang, Jun
Author_xml – sequence: 1
  givenname: Longbin
  surname: Zhang
  fullname: Zhang, Longbin
  organization: Institute of Life Sciences, Chongqing Medical University
– sequence: 2
  givenname: Liyong
  surname: Zou
  fullname: Zou, Liyong
  organization: Institute of Life Sciences, Chongqing Medical University
– sequence: 3
  givenname: Xuejun
  surname: Jiang
  fullname: Jiang, Xuejun
  organization: Center of Experimental Teaching for Public Health, Experimental Teaching and Management Center, Chongqing Medical University
– sequence: 4
  givenname: Shuqun
  surname: Cheng
  fullname: Cheng, Shuqun
  organization: Department of Occupational and Environmental Health, School of Public Health and Management, Chongqing Medical University
– sequence: 5
  givenname: Jun
  surname: Zhang
  fullname: Zhang, Jun
  organization: Institute of Life Sciences, Chongqing Medical University
– sequence: 6
  givenname: Xia
  surname: Qin
  fullname: Qin, Xia
  organization: Department of Pharmacy, The First Affiliated Hospital of Chongqing Medical University
– sequence: 7
  givenname: Zhexue
  surname: Qin
  fullname: Qin, Zhexue
  organization: Institute of Cardiovascular Diseases of PLA, the Second Affiliated Hospital, Third Military Medical University (Army Medical University)
– sequence: 8
  givenname: Chengzhi
  orcidid: 0000-0002-1087-4911
  surname: Chen
  fullname: Chen, Chengzhi
  organization: Dongsheng Lung-Brain Disease Joint Lab, Chongqing Medical University
– sequence: 9
  givenname: Zhen
  orcidid: 0000-0002-1651-591X
  surname: Zou
  fullname: Zou, Zhen
  organization: Dongsheng Lung-Brain Disease Joint Lab, Chongqing Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33971103$$D View this record in MEDLINE/PubMed
BookMark eNqFkU9vEzEQxS1URP_ARwBZ4sJlg71e78biQlUVilTRA3C2Jva4deXYwfYC6afvLkkuPcBprNHvjZ_eOyVHMUUk5DVnC86W7D0fOiGFYouWtXzBFVdCsGfkZN43smPd0eE9QcfktJR7xmTf9vwFORZCDZwzcUK23yqsfPAPUH2KNDn6NbuWBgTr4y2tiV7dNJyCqf7XDtnkVNHUQuEWfCyVPvhoaPrjLdIIMW0gV28ClsZHOxq0FKNN9Q6Dh0ANhkAtQr17SZ47CAVf7ecZ-fHp8vvFVXN98_nLxfl1YyQbasOlAmMNmp4B9ii5cVwtUTGrGHcgTCeUBCes44z1HQ6yE6sBWzYovpJTRGfk3e7uZPzniKXqtS-zDYiYxqJb2cq-552c0bdP0Ps05ji5m6ie8X45LNVEvdlT42qNVm-yX0Pe6kOoE_BhB5icSsnotPH1b3g1gw-aMz1XqA8V6rlCva9wUssn6sMH_9N93Ol8dCmv4XfKweoK25CyyxCNL1r8-8Qj9dKx7w
CitedBy_id crossref_primary_10_1002_advs_202106049
crossref_primary_10_1016_j_jtemb_2025_127618
crossref_primary_10_3389_ftox_2022_974429
crossref_primary_10_1016_j_jhazmat_2024_134440
crossref_primary_10_1039_D3BM00271C
crossref_primary_10_1165_rcmb_2021_0515OC
crossref_primary_10_1080_15376516_2024_2431687
crossref_primary_10_1016_j_etap_2024_104469
crossref_primary_10_1186_s12951_022_01486_7
crossref_primary_10_3390_molecules27185755
crossref_primary_10_1016_j_toxlet_2022_11_002
crossref_primary_10_33549_physiolres_935330
crossref_primary_10_3390_v14122799
crossref_primary_10_2147_IJN_S386240
crossref_primary_10_1007_s11356_022_19821_8
crossref_primary_10_1016_j_jep_2023_117619
crossref_primary_10_3389_fphar_2024_1360177
Cites_doi 10.1172/JCI60331
10.1016/j.drudis.2017.08.006
10.1038/cddis.2017.337
10.1166/jbn.2019.2696
10.1021/nn800511k
10.1007/s00395-014-0450-9
10.1186/1743-8977-8-27
10.1038/srep43126
10.1016/j.toxlet.2017.12.025
10.1016/j.cell.2012.03.042
10.2147/IJN.S224179
10.1002/med.21396
10.1155/2018/1062562
10.5402/2012/372505
10.1161/CIRCRESAHA.116.306588
10.1038/ncb2021
10.1146/annurev-pharmtox-011112-140320
10.1016/j.cell.2013.12.010
10.3390/nano7110354
10.1038/nri2171
10.1093/nar/gkaa631
10.1080/17435390.2018.1513094
10.1242/jcs.222836
10.1016/S0009-2614(02)01106-5
10.1080/17435390.2018.1537409
10.1021/la104825u
10.1146/annurev.pharmtox.010909.105600
10.1089/ars.2017.7342
10.1016/j.freeradbiomed.2018.09.032
10.1146/annurev.pharmtox.46.120604.141046
10.1289/EHP424
10.1002/smll.202000963
10.1126/science.1114397
10.2147/NSA.S23932
10.1074/jbc.M209195200
10.1186/s12989-019-0328-y
10.1021/acsami.7b11219
10.1128/MCB.26.1.221-229.2006
10.3109/10408444.2015.1137864
10.1212/WNL.0000000000008861
10.2147/IJN.S250367
10.1155/2017/9237263
10.2147/IJN.S121956
10.2174/1566524013666131111130058
10.3390/molecules190710074
10.1080/15548627.2021.1911016
10.1002/adma.201301732
ContentType Journal Article
Copyright 2021 Informa UK Limited, trading as Taylor & Francis Group 2021
2021 Informa UK Limited, trading as Taylor & Francis Group
Copyright_xml – notice: 2021 Informa UK Limited, trading as Taylor & Francis Group 2021
– notice: 2021 Informa UK Limited, trading as Taylor & Francis Group
DBID AAYXX
CITATION
NPM
K9.
7X8
DOI 10.1080/17435390.2021.1919330
DatabaseName CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
PubMed
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitleList
PubMed
MEDLINE - Academic
ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1743-5404
EndPage 797
ExternalDocumentID 33971103
10_1080_17435390_2021_1919330
1919330
Genre Research Article
Journal Article
GroupedDBID ---
00X
0BK
0R~
123
4.4
53G
AALUX
AAMIU
AAPUL
AAQRR
ABBKH
ABDBF
ABEIZ
ABJNI
ABLIJ
ABLKL
ABUPF
ABXYU
ACENM
ACGEJ
ACIEZ
ACPRK
ACUHS
ADCVX
ADXPE
AECIN
AENEX
AEOZL
AFRAH
AGDLA
AGFJD
AGRBW
AGYJP
AIJEM
AIRBT
AKBVH
ALMA_UNASSIGNED_HOLDINGS
ALQZU
ALYBC
BABNJ
BLEHA
BOHLJ
CCCUG
CS3
DKSSO
DU5
EBD
EBS
EMOBN
ESX
F5P
H13
HZ~
KRBQP
KSSTO
KWAYT
KYCEM
LJTGL
M4Z
MM.
O9-
P2P
RNANH
RVRKI
SV3
TBQAZ
TDBHL
TERGH
TFL
TFW
TUROJ
TUS
UHWXJ
V1S
~1N
AAGDL
AAYXX
ABWVI
ADYSH
AFRVT
AMPGV
CITATION
NPM
K9.
TASJS
7X8
ID FETCH-LOGICAL-c507t-159acdcec60ae6e51cf198e90d901fa3c4395af3df10064e7543b7e20791b5353
ISSN 1743-5390
1743-5404
IngestDate Fri Jul 11 01:10:40 EDT 2025
Wed Aug 13 11:15:25 EDT 2025
Wed Feb 19 02:27:36 EST 2025
Thu Apr 24 23:04:55 EDT 2025
Tue Jul 01 03:28:08 EDT 2025
Wed Dec 25 09:07:24 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords ZnONPs
ubiquitin-proteasome system
HO-1
Nrf2
antioxidative response
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c507t-159acdcec60ae6e51cf198e90d901fa3c4395af3df10064e7543b7e20791b5353
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-1651-591X
0000-0002-1087-4911
OpenAccessLink https://figshare.com/articles/journal_contribution/Stabilization_of_Nrf2_leading_to_HO-1_activation_protects_against_zinc_oxide_nanoparticles-induced_endothelial_cell_death/14569280
PMID 33971103
PQID 2560168789
PQPubID 2043362
PageCount 19
ParticipantIDs proquest_miscellaneous_2525661455
pubmed_primary_33971103
proquest_journals_2560168789
informaworld_taylorfrancis_310_1080_17435390_2021_1919330
crossref_citationtrail_10_1080_17435390_2021_1919330
crossref_primary_10_1080_17435390_2021_1919330
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-03
PublicationDateYYYYMMDD 2021-07-03
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-03
  day: 03
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: Abingdon
PublicationTitle Nanotoxicology
PublicationTitleAlternate Nanotoxicology
PublicationYear 2021
Publisher Taylor & Francis
Taylor & Francis Ltd
Publisher_xml – name: Taylor & Francis
– name: Taylor & Francis Ltd
References CIT0030
CIT0010
CIT0032
CIT0031
CIT0012
CIT0034
CIT0011
CIT0033
CIT0014
CIT0036
CIT0013
CIT0035
CIT0016
CIT0038
CIT0015
CIT0037
CIT0018
CIT0017
CIT0039
CIT0019
CIT0041
CIT0040
CIT0021
CIT0043
CIT0020
CIT0042
CIT0001
CIT0023
CIT0045
CIT0022
CIT0044
CIT0003
CIT0025
CIT0047
CIT0002
CIT0024
CIT0046
CIT0005
CIT0027
CIT0004
CIT0026
CIT0007
CIT0029
CIT0006
CIT0028
CIT0009
CIT0008
References_xml – ident: CIT0018
  doi: 10.1172/JCI60331
– ident: CIT0019
  doi: 10.1016/j.drudis.2017.08.006
– ident: CIT0045
  doi: 10.1038/cddis.2017.337
– ident: CIT0038
  doi: 10.1166/jbn.2019.2696
– ident: CIT0041
  doi: 10.1021/nn800511k
– ident: CIT0002
  doi: 10.1007/s00395-014-0450-9
– ident: CIT0001
  doi: 10.1186/1743-8977-8-27
– ident: CIT0012
  doi: 10.1038/srep43126
– ident: CIT0035
  doi: 10.1016/j.toxlet.2017.12.025
– ident: CIT0003
  doi: 10.1016/j.cell.2012.03.042
– ident: CIT0014
  doi: 10.2147/IJN.S224179
– ident: CIT0015
  doi: 10.1002/med.21396
– ident: CIT0005
  doi: 10.1155/2018/1062562
– ident: CIT0032
  doi: 10.5402/2012/372505
– ident: CIT0021
  doi: 10.1161/CIRCRESAHA.116.306588
– ident: CIT0011
  doi: 10.1038/ncb2021
– ident: CIT0016
  doi: 10.1146/annurev-pharmtox-011112-140320
– ident: CIT0043
  doi: 10.1016/j.cell.2013.12.010
– ident: CIT0009
  doi: 10.3390/nano7110354
– ident: CIT0022
  doi: 10.1038/nri2171
– ident: CIT0031
  doi: 10.1093/nar/gkaa631
– ident: CIT0006
  doi: 10.1080/17435390.2018.1513094
– ident: CIT0026
  doi: 10.1242/jcs.222836
– ident: CIT0047
  doi: 10.1016/S0009-2614(02)01106-5
– ident: CIT0039
  doi: 10.1080/17435390.2018.1537409
– ident: CIT0025
  doi: 10.1021/la104825u
– ident: CIT0004
  doi: 10.1146/annurev.pharmtox.010909.105600
– ident: CIT0033
  doi: 10.1089/ars.2017.7342
– ident: CIT0044
  doi: 10.1016/j.freeradbiomed.2018.09.032
– ident: CIT0007
  doi: 10.1146/annurev.pharmtox.46.120604.141046
– ident: CIT0030
  doi: 10.1289/EHP424
– ident: CIT0040
  doi: 10.1002/smll.202000963
– ident: CIT0020
  doi: 10.1126/science.1114397
– ident: CIT0034
  doi: 10.2147/NSA.S23932
– ident: CIT0029
  doi: 10.1074/jbc.M209195200
– ident: CIT0028
  doi: 10.1186/s12989-019-0328-y
– ident: CIT0036
  doi: 10.1021/acsami.7b11219
– ident: CIT0010
  doi: 10.1128/MCB.26.1.221-229.2006
– ident: CIT0013
  doi: 10.3109/10408444.2015.1137864
– ident: CIT0017
  doi: 10.1212/WNL.0000000000008861
– ident: CIT0024
  doi: 10.2147/IJN.S250367
– ident: CIT0027
  doi: 10.1155/2017/9237263
– ident: CIT0037
  doi: 10.2147/IJN.S121956
– ident: CIT0046
  doi: 10.2174/1566524013666131111130058
– ident: CIT0008
  doi: 10.3390/molecules190710074
– ident: CIT0023
  doi: 10.1080/15548627.2021.1911016
– ident: CIT0042
  doi: 10.1002/adma.201301732
SSID ssj0056261
Score 2.3737566
Snippet With the abundant production and wide application of zinc oxide nanoparticles (ZnONPs), the potential health risks of ZnONPs have raised serious concerns....
SourceID proquest
pubmed
crossref
informaworld
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 779
SubjectTerms antioxidative response
Aorta
Apoptosis
Blood vessels
Cell activation
Cell death
Endothelial cells
Health risks
HO-1
Mortality
Nanoparticles
Nrf2
NRF2 protein
Oxidative stress
Proteasomes
Regulatory mechanisms (biology)
Stabilization
Toxicity
Ubiquitin
ubiquitin-proteasome system
Zinc oxide
Zinc oxides
ZnONPs
Title Stabilization of Nrf2 leading to HO-1 activation protects against zinc oxide nanoparticles-induced endothelial cell death
URI https://www.tandfonline.com/doi/abs/10.1080/17435390.2021.1919330
https://www.ncbi.nlm.nih.gov/pubmed/33971103
https://www.proquest.com/docview/2560168789
https://www.proquest.com/docview/2525661455
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF5BeuGCeBMoaJFQL66D37GPbWkUoZD24EgRF8veR2tU2dDYEsmvZ8a7dhwR1MLFija7tuX5PPvN551ZQj4yL-S2yDwztUNpejIK4JXKXFPaIUzWXGacoaD_dR5MF96Xpb_sfTHF7JIqG7HN3ryS_7EqtIFdMUv2HyzbnRQa4DfYF45gYTjey8bAFHFt66ajffNb6eBGEE2mCrDK6YVpN-UylPBq6KoMKyO9SnMghsYmL5hR_sq5MIq0gABar5MzIVSvcWmAKDjmaN2gsI4iv8GRM_YpLfjnsoJTsB2BvhOiZ2VxleUdBL-VtZIC1qWeM3H5Tq47L2vxve76nl0LLWZf1z91sxYoHLtZzOr2fCpWQQViqHQDsaetdcR-D3B9rzpW-8384e3V8kg8l-9G1ggvPoL4EzWa7fTWftKfXySTxWyWxOfL-CE5cCCscAbk4OT08-mknbuBDKoKu-3ttTlfofVp72V22MxOrdu_RywNc4mfkMc65KAnyrRPyQNRPCNHl6pm-fqYxtsUvNUxPaKX22rm6-dkvQMyWkqKIKMaZLQqKYKMbkFGW5BRDTKKIKMNyOhekNEeyCiCjDYge0EWk_P4bGrq_TpMBlFFZQIzThlnggVWKgLh20zaUSgiiwPplKnLgPz6qXS5tJEJi7HvudlYONYY3IMPD_clGRRlIV4TGthMuE4GXMlhnseDiPtOKCFciCDAldIbEq997gnTxexxT5WbxNY1b1tzJWiuRJtrSEbdsB-qmstdA6K-UZOqkdGk2vMmce8Ye9giINFOY5U0CkgQjsNoSD50f4NLx6ebFqKssQ_0CnAHgSF5pZDT3a0L8QMwdvfNPUa_JY-27-MhGVS3tXgHFLrK3mvc_wbq0sOG
linkProvider EBSCOhost
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Stabilization+of+Nrf2+leading+to+HO-1+activation+protects+against+zinc+oxide+nanoparticles-induced+endothelial+cell+death&rft.jtitle=Nanotoxicology&rft.au=Zhang%2C+Longbin&rft.au=Zou%2C+Liyong&rft.au=Jiang%2C+Xuejun&rft.au=Cheng%2C+Shuqun&rft.date=2021-07-03&rft.issn=1743-5404&rft.eissn=1743-5404&rft.volume=15&rft.issue=6&rft.spage=779&rft_id=info:doi/10.1080%2F17435390.2021.1919330&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1743-5390&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1743-5390&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1743-5390&client=summon